PDCD1 and myocarditis: ICI-related myocarditis is a rare but potentially fatal complication of cancer immunotherapy, with reported incidences between 0.09% and 1.14%, which can nearly double with combination therapies using CTLA-4 and PD-1 inhibitors [8,11,36,57].